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Paolo Spirito, MDH ypertrophic cardiomyopathy (HCM) wasinitially described as an uncommonand largely untreatable disorder, a view
derived from small cohorts of highly selected and
severely symptomatic patients evaluated at major
HCM referral centers many decades ago (1,2). This
misleading perception of HCM persists among many
clinicians and is often reinforced in patients by con-
tradictory information derived from social media
and the Internet. HCM patients deserve better. The
reality is that in barely 1 generation of investigators,
this disease has evolved from a grim and largely
untreatable condition to a treatable disorder asso-
ciated with a normal or nearly normal life expec-
tancy in most patients. This remarkable result has
been achieved by a more balanced understanding
of the natural history of HCM in less selected pa-
tient populations (3,4) and through major advances
in cardiovascular therapy, including implantable
cardioverter-deﬁbrillators (ICDs) for primary preven-
tion of sudden death, surgical septal myectomy for
relief of progressive heart failure symptoms in pa-
tients with left ventricle (LV) outﬂow obstruction,
and transplantation and other supportive mechanical
therapies in the minority of non-obstructive cardiac
disease patients with advanced heart failure unre-
sponsive to pharmacologic treatment (5–12).SEE PAGE 1915In this issue of the Journal, Maron et al. (13) report
the clinical course of 1,000 consecutive adult patients
with HCM evaluated at 2 HCM referral centers over a
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Appropriate ICD interventions, heart transplantation,
and out-of-hospital resuscitation from cardiac arrest
prevented deaths in 56 of the study patients. Of the
258 patients who underwent septal reduction therapy
(surgical myectomy in most), 90% were alive almost
10 years after the procedure, most with mild or no
symptoms. Only 40 study patients died of HCM-
related causes during follow-up. Of these patients,
17 died suddenly, 12 because they either declined ICD
implantation or were evaluated in the 1990s, before
the ICD had become part of HCM management;
4 others did not have implants because they did not
have major conventional risk factors; and 1 had an
ICD known to malfunction by the manufacturer, an
extensively reported clinical case (14). It is fair to
assume that these patients would not have died
suddenly if they had had an ICD. Of the remaining 23
patients whose deaths were HCM-related, 17 died of
advanced heart failure (with or without heart trans-
plants) in the absence of LV outﬂow obstruction.
Therefore, the dominant cause of HCM-related mor-
tality in this large consecutive cohort changed from
sudden and unexpected death to death due to
advanced heart failure.
Results of this study show what contemporary
management in a referral HCM population can ach-
ieve. The rate of HCM-related death was 0.5%/year, an
event rate well below that reported decades ago for
this disease and not different from that of the general
U.S. population (13). This event rate could serve as a
target for HCM management. These ﬁndings also
show that the greatest challenge in the management
of patients with HCM is gradually shifting from pre-
vention of sudden death as the predominant threat to
the management of heart failure symptoms in the
absence of LV outﬂow obstruction. This is a major step
forward in treating a disease in which most instances
of sudden deaths occur in young and asymptomatic
patients who have the expectation of many years of
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1930rewarding life and deserve this aspiration to be ful-
ﬁlled by modern cardiovascular medicine.
Do we now have all the answers to manage the risk
of sudden death in HCM? Without doubt, many HCM
patients worldwide are still alive today because of the
ICD. However, do all HCM patients who have received
ICD implants deﬁnitely need the device? This question
is not conﬁned to this disorder; it is clearly a problem
with risk stratiﬁcation for sudden death in cardiovas-
cular disease and coronary artery disease, other car-
diomyopathies and arrhythmogenic genetic diseases
alike. In the present study byMaron at al. (13), the ratio
of the total number of implanted ICDs to devices that
intervened appropriately during follow-up was 9:1,
not substantially different from that in large random-
ized trials of patients with LV systolic dysfunction and
congestive heart failure due to ischemic or non-
ischemic causes (15). This 9:1 ratio is probably higher
than we would like and can be largely explained by the
persisting uncertainties in risk stratiﬁcation for indi-
vidual patients with HCM (16,17). An equally valid
question iswhat ratiowouldwe consider acceptable? It
is unrealistic to expect that we will ever arrive at a 4:1
or 3:1 ratio, and we will never reach a 1:1 ratio. In HCM,
the extreme disease heterogeneity and relatively low
absolute number of sudden deaths constitute imped-
iments to achieving such goals. Furthermore, due to
these difﬁculties in risk stratiﬁcation, the decision of
whether to implant an ICD often requires an open
discussion with the patient about the beneﬁts andpotential complications of the device, as well as the
strength of the available evidence for risk assessment
(18). Therefore, the individual patient’s personal and
psychological attitude toward the risk of sudden death
contributes to the ﬁnal decision and the number
of implanted ICDs, a number also inﬂuenced by prob-
lems of legal liability perceived by clinicians.
However, several positive aspects of this complex
issue must be kept in mind. As the result of better
contemporary ICD programming, improved tech-
nology, and more experienced electrophysiologists,
inappropriate shock rates are now much lower. An-
other important aspect not generally addressed in
published reports is the psychological beneﬁt that
patients derive from being relieved from the constant
fear of sudden death, a feeling fully appreciated only
by those who have been exposed to the unpredictable
risk of this event.
In conclusion, as shown by Maron et al. (13),
contemporary treatments can fulﬁll the expectations
of many patients with HCM by effectively preventing
sudden death, extending life expectancy, and im-
proving quality of life in a complex genetic disease
associated, in this cohort, with a low mortality not
dissimilar from that of the general population.
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